Carlyle Group Inc. - PARATEK PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
Carlyle Group Inc. ownership history of PARATEK PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$2,300,900
-12.3%
1,041,1310.0%0.08%
+5.1%
Q1 2023$2,623,6501,041,1310.08%
Other shareholders
PARATEK PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Omega Fund Management, LLC 2,600,410$33,805,00033.22%
Abingworth LLP 1,041,131$13,535,0008.41%
Roumell Asset Management, LLC 197,347$2,566,0005.65%
Trellus Management Company, LLC 89,700$1,166,0002.12%
Prosight Management, LP 148,682$1,933,0001.21%
Broadfin Capital, LLC 477,607$6,209,0000.97%
HIGHLAND CAPITAL MANAGEMENT LP 959,278$12,471,0000.64%
ARMISTICE CAPITAL, LLC 580,000$7,540,0000.58%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,500$1,346,0000.52%
Opus Point Partners Management, LLC 20,000$260,0000.51%
View complete list of PARATEK PHARMACEUTICALS INC shareholders